Grant: CIHR Fellowship
Direct Payment
$145,833.00
Inhibitors of Kaposi's sarcoma herpesvirus LANA function
FY 2009-10
Summary
Kaposi's sarcoma herpesvirus (KSHV) has a causative role in several human cancers including Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multi-centric Castleman's disease. KS was first described among Mediteranean and African men, where it is a frequent disease. Furthermore, KS is the most common AIDS associated cancer in the world. In order to cause cancer, KSHV infects cells that become tumor cells. KSHV persists in tumor cells in the form of multiple viral circular DNA molecules. A single viral protein, termed LANA, is essential to maintain KSHV infection in these cells. It was shown that the viral protein LANA is responsible to tether the viral circular DNA molecules to cellular chromosomes. This function of LANA allows the viral DNA to separate equally in each daughter cell after cellular division. In KSHV-infected tumor cells, if the bridge between viral DNA, LANA and cellular chromosomes is disrupted, LANA will no longer be able to allow the virus to persist in the cells and the tumor cells will die.
This work investigates for compounds that inhibit LANA's function, to provide new tools for KSHV studies and potential therapies for patients suffering from KSHV associated cancer. We have developed and miniaturized a robust screening of chemical compounds to identify those that are capable of disrupting LANA binding to chromosomes. So far, we have screened 50,000 compounds from the Institute of Chemistry and Cell Biology (ICCB) of Harvard and we are planning to screen ~450,000 more compounds, both at the ICCB and the Broad Institute of Massachusetts Institute of Technology (MIT)/Harvard. We will have to verify that potent compounds will be specific for the inhibition of LANA binding to chromosomes but also that these compounds are not toxic for the cells.
There are currently no specific therapies for any KSHV tumors. Small molecules identified in this work will serve as potential agents to prevent and treat KSHV tumors.
Department
Program
CIHR Fellowship
Recipient
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
203736
Name
Beauchemin Chantal
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Inhibitors of Kaposi's sarcoma herpesvirus LANA function
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$145,833
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Antiviral; Co-Precipitation; Confocal Microscopy; Cytotoxicity; Episome Maintenance; Fluorescence Polarization; Inhibitors; Kaposi'S Sarcoma Herpesvirus; Latency; Structure-Activity Relationship
Abstract
Kaposi's sarcoma herpesvirus (KSHV) has a causative role in several human cancers including Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multi-centric Castleman's disease. KS was first described among Mediteranean and African men, where it is a frequent disease. Furthermore, KS is the most common AIDS associated cancer in the world. In order to cause cancer, KSHV infects cells that become tumor cells. KSHV persists in tumor cells in the form of multiple viral circular DNA molecules. A single viral protein, termed LANA, is essential to maintain KSHV infection in these cells. It was shown that the viral protein LANA is responsible to tether the viral circular DNA molecules to cellular chromosomes. This function of LANA allows the viral DNA to separate equally in each daughter cell after cellular division. In KSHV-infected tumor cells, if the bridge between viral DNA, LANA and cellular chromosomes is disrupted, LANA will no longer be able to allow the virus to persist in the cells and the tumor cells will die.
This work investigates for compounds that inhibit LANA's function, to provide new tools for KSHV studies and potential therapies for patients suffering from KSHV associated cancer. We have developed and miniaturized a robust screening of chemical compounds to identify those that are capable of disrupting LANA binding to chromosomes. So far, we have screened 50,000 compounds from the Institute of Chemistry and Cell Biology (ICCB) of Harvard and we are planning to screen ~450,000 more compounds, both at the ICCB and the Broad Institute of Massachusetts Institute of Technology (MIT)/Harvard. We will have to verify that potent compounds will be specific for the inhibition of LANA binding to chromosomes but also that these compounds are not toxic for the cells.
There are currently no specific therapies for any KSHV tumors. Small molecules identified in this work will serve as potential agents to prevent and treat KSHV tumors.
Competitiondate
201002
Approvedterm2
2 yrs 11 mths
Pinamesdelim
Beauchemin, Chantal
Approvedterm
2 ans 11 mois
Cihrcontribution2
~ $145,833~ $0~